4D Molecular Therapeutics (US.FDMT)
Capital Allocation Audit · Period: 2017 – 2026
Key Metrics
US.FDMT · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.0% | → |
| ROE | -15.2% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.05 | ↑ |
| Gross Margin | 0.0% | ↓ |
US.FDMT (4D Molecular Therapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 100.0% → ROE -15.2% ↓ Cash Conversion - → D/E Ratio 0.05 ↑ Gross Margin 0.0% ↓
Key Metrics
US.FDMT (4D Molecular Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 100.0% →ROE -15.2% ↓Cash Conversion - →D/E Ratio 0.05 ↑Gross Margin 0.0% ↓Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies